A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer

Documenti analoghi

• PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer
  di: Philip Sutera, et al.
  Pubblicazione: (2024)
• Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
  di: Thomas Büttner, et al.
  Pubblicazione: (2024)
• Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients
  di: Tokiyoshi Tanegashima, et al.
  Pubblicazione: (2024)
• Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer
  di: Umang Swami, et al.
  Pubblicazione: (2024)
• Reply to Letter to the Editor on “Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients”
  di: Tokiyoshi Tanegashima, et al.
  Pubblicazione: (2024)